Open Access23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults
Author(s) -
Christine Watera,
Jessica Nakiyingi,
George Miiro,
Richard Muwonge,
James Whitworth,
Charles F. Gilks,
Neil French
Publication year - 2004
Publication title -
aids
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200405210-00018
Subject(s) - hazard ratio , medicine , pneumococcal polysaccharide vaccine , pneumococcal vaccine , vaccination , confidence interval , streptococcus pneumoniae , pneumococcal pneumonia , pneumonia , pneumococcal infections , human immunodeficiency virus (hiv) , immunology , pneumococcal disease , microbiology and biotechnology , biology , antibiotics
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], but surprisingly a survival advantage favouring vaccination (HR 0.84; CI 0.7-1.0). An explanation for the improvement in survival in the face of excess morbid events is lacking; a role for vaccine in HIV care in Africa remains unlikely.